Ligand Pharmaceuticals Incorpor
LGND
Positions held
Your positionsLGND isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Ligand Pharmaceuticals has a strong competitive edge in the biotechnology sector, driven by its innovative drug development strategies and partnerships with major pharmaceutical companies.
- Revenue increased by 23% compared to the prior quarter, reaching $64 million.
- Gross margin improved to 95%, up from 93.7% in the previous quarter.
- The biotechnology industry is facing regulatory challenges that could impact the approval timelines of new drugs, potentially affecting Ligand's growth.
- Operating margin compressed to 13.5%, indicating potential cost pressures.
- Net income for the most recent quarter was $48.508 million, down from $117.273 million in the previous quarter.
Fundamentals
| Market cap | $5.88B | Enterprise value | $5.65B | Trailing P/E | 31.09 | Forward P/E | 24.69 |
| PEG | 1.53 | Price / book | 6.07 | Beta | 1.01 | Dividend yield | 0.00% |
| Revenue growth | 33.7% | Earnings growth | 825.0% | Gross margin | 81.2% | Operating margin | 13.5% |
| Profit margin | 67.9% | ROE | 22.0% | ROA | 4.0% | Debt / equity | 1.17 |
| Current ratio | 31.18 | Free cash flow | $139.75M | Analyst recommendation | strong_buy | Mean target | $344.25 |
| 52w high | $326.63 | 52w low | $175.89 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $63.7M | $51.7M | $59.7M | $115M | $47.6M |
| Op margin | 13.5% | 33.6% | 33.6% | 46.9% | 20.4% |
| Net income | $48.5M | -$13.3M | $44.8M | $117M | $4.8M |
| Gross margin | 95.0% | 93.7% | 95.0% | 96.7% | 93.9% |
| Gross profit | $60.5M | $48.4M | $56.7M | $112M | $44.7M |
| Operating income | $8.6M | $17.4M | $20.0M | $54.1M | $9.7M |
- Revenue +23% vs prior quarter ($64M vs $52M).
- Gross margin 95% (was 93.7% prior quarter).
- Operating margin compressed to 13.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $268M | $167M | $131M | $196M | — |
| Op margin | 17.6% | 13.8% | 7.5% | 1.5% | — |
| Net income | $124M | -$4.0M | $52.2M | -$33.4M | — |
| Gross margin | 94.6% | 93.4% | 92.0% | 73.1% | — |
| Gross profit | $254M | $156M | $121M | $143M | — |
| Operating income | $47.2M | $23.0M | $9.8M | $3.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-29 · Is Ligand Pharmaceuticals (LGND) Below Fair Value As It Funds AvenCell?
2026-09-29 · Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal
2026-09-29 · Is Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook?
2026-09-27 · Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones
2026-09-25 · Twilio downgraded, Synopsys upgraded: Wall Street's top analyst calls
2026-09-25 · Barclays Initiates Ligand Pharmaceuticals at Overweight With $345 Price Target
2026-09-24 · Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell
2026-09-22 · Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
2026-09-22 · Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
2026-09-22 · Ligand Pharmaceuticals Acquires Ryjunea Royalty Interest for $23 Million
2026-09-22 · Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
Price (daily)
Full chart · RSI · MACD · patterns